Anti-CYP4V2 antibody - C-terminal (ab173150)

Overview

  • Product name
    Anti-CYP4V2 antibody - C-terminal
    See all CYP4V2 primary antibodies
  • Description
    Rabbit polyclonal to CYP4V2 - C-terminal
  • Tested applications
    Suitable for: WBmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide within Human CYP4V2 aa 495-525 (C terminal) conjugated to Keyhole Limpet Haemocyanin (KLH). The exact sequence is proprietary.
    Database link: Q6ZWL3

  • Positive control
    • NCI-H460 cell line lysates.

Properties

Applications

Our Abpromise guarantee covers the use of ab173150 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/100 - 1/500. Predicted molecular weight: 61 kDa.

Target

  • Function
    Catalyzes the omega-hydroxylation of medium-chain saturated fatty acids such as laurate, myristate and palmitate in an NADPH-dependent pathway. The substrate specificity is higher for myristate > laurate > palmitate (C14>C16>C12). May have a role in fatty acid and steroid metabolism in the eye.
  • Tissue specificity
    Broadly expressed. Detected in heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas, retina, retinal pigment epithelium (RPE) and lymphocytes.
  • Involvement in disease
    Bietti crystalline corneoretinal dystrophy (BCD) [MIM:210370]: An autosomal recessive ocular disease characterized by retinal degeneration and marginal corneal dystrophy. Typical features include multiple glistening intraretinal crystals scattered over the fundus, a characteristic degeneration of the retina, and sclerosis of the choroidal vessels, ultimately resulting in progressive night blindness and constriction of the visual field. Most patients have similar crystals at the corneoscleral limbus. Patients develop decreased vision, nyctalopia, and paracentral scotomata between the 2nd and 4th decade of life. Later, they develop peripheral visual field loss and marked visual impairment, usually progressing to legal blindness by the 5th or 6th decade of life. Note=The disease is caused by mutations affecting the gene represented in this entry.
  • Sequence similarities
    Belongs to the cytochrome P450 family.
  • Cellular localization
    Endoplasmic reticulum membrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • BCD antibody
    • CP4V2_HUMAN antibody
    • CYP4AH1 antibody
    • CYP4V 2 antibody
    • CYP4V2 antibody
    • Cytochrome P450 4V2 antibody
    • Cytochrome P450, family 4, subfamily V, polypeptide 2 antibody
    • Retina CYP4V2 antibody
    see all

Images

  • Anti-CYP4V2 antibody - C-terminal (ab173150) at 1/100 dilution + NCI-H460 cell line lysates at 35 µg

    Predicted band size : 61 kDa

References

ab173150 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab173150.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up